The 69th meeting of the Medicines Classification Committee will include an agenda item on the down-scheduling of low dose cannabidiol (CBD) from Schedule 4 (Prescription Only) to Schedule 3 (Pharmacist Only) under certain conditions by the TGA in Australia. Low dose cannabidiol refers to daily dose of <150 mg.
Medsafe and the Medicinal Cannabis Agency have provided some regulatory advice on this harmonisation item at: CBD Harmonisation Regulatory Guidance
If you would like to comment on this item, please visit MCC Submissions
Medsafe encourages those making comments on this item to consider the classification and supply of low dose CBD in the context of New Zealand legislation.
The closing date for comments is Monday 3rd October 2022, 5pm NZST.
A full agenda for the meeting can be found on the Medsafe Website: Agenda 69th meeting of the Medicines Classification Committee
If you have any further questions, please email the Medicinal Cannabis Agency at: medicinal_cannabis@health.
